#United States #Paragon 28 #Zimmer Biomet #medical technology #Englewood

Zimmer Biomet's Acquisition of Paragon 28: A Strategic Leap into the Foot and Ankle Sector

In a noteworthy development in the medical technology industry, Zimmer Biomet Holdings, Inc., a leading global entity in the sector, has inked a definitive agreement to acquire Paragon 28, Inc. This acquisition is set to reshape the competitive landscape of foot and ankle care, a sector projected to be worth approximately $5 billion.

Key Deal Highlights

The agreement entails Zimmer Biomet purchasing all outstanding shares of Paragon 28 for $13.00 per share in cash, reaching an equity value of about $1.1 billion. Furthermore, Paragon 28 shareholders will gain a non-tradeable contingent value right (CVR), potentially adding up to $1.00 per share contingent upon meeting specified revenue milestones during Zimmer Biomet's fiscal year 2026.

The boards of directors from both companies have indicated unanimous approval of this strategic venture. The acquisition not only enhances Zimmer Biomet's financial profile but also promises immediate accretion to revenue growth and adjusted earnings per share (EPS).

Strengthening Market Position

Founded in 2010, Paragon 28 has made its mark with an extensive range of surgical offerings that address critical areas within the foot and ankle domain, including joint replacements and trauma solutions. The company has displayed a continuous commitment to innovation, filling unmet needs in this specialized area.

Ivan Tornos, President and CEO of Zimmer Biomet, highlighted that this acquisition diversifies their portfolio beyond traditional orthopedics, strategically positioning them in a high-growth segment of musculoskeletal care. The integration of Paragon 28’s diverse product pipeline into Zimmer Biomet's global network is expected to deliver improved outcomes for patients while offering cross-selling opportunities, particularly in the rapidly expanding Ambulatory Surgery Center (ASC) market.

Financial Benefits and Growth Prospects

The financial implications of the acquisition are significant. In 2024, Paragon 28 announced projected net revenues ranging from $255.9 to $256.2 million, showcasing robust growth. Zimmer Biomet anticipates that the acquisition will be approximately 3% dilutive to adjusted EPS in 2025 but expects the earnings impact to shift positively within 24 months post-acquisition close.

This move is poised to accelerate Zimmer Biomet’s growth in a sector benefiting from increased awareness and advancements in foot and ankle care solutions. It is evident that both companies share a vision of improved patient outcomes—aiming to bring groundbreaking solutions to an area of significant medical need.

Timeline and Next Steps

The closing of the transaction is subject to regulatory approvals and shareholder consent from Paragon 28, with an anticipated completion in the first half of 2025. Zimmer Biomet has engaged Goldman Sachs & Co. LLC as its exclusive financial advisor for this deal, while Hogan Lovells US LLP serves as their legal advisory team. Paragon 28, conversely, has enlisted Piper Sandler & Co. as its financial advisor, along with Cravath, Swaine & Moore LLP as legal counsel.

This acquisition heralds a new chapter for both companies, with Zimmer Biomet set to enhance its capabilities in the foot and ankle market while advancing Paragon 28's mission through an established global platform.

For continuous updates on the implications of this acquisition and expected financial outcomes, stakeholders can tune in to Zimmer Biomet’s fourth quarter 2024 earnings call scheduled for February 6, 2025. As the landscape of orthopedic care evolves, both companies remain committed to leading innovation and improving patient care in every sense.